The study constructed allogeneic anti‐CLL‐1 CAR‐T cell therapy for the treatment of relapsed or refractory AML (r/r AML) by five edits: TRAC KO, human anti‐CLL‐1 CAR‐specific insertion into the TRAC gene, PD‐1 KO, B2M‐HLA‐E insertion, and endogenous B2M KO. The gene discussed is B2M; the disease is acute myeloid leukemia.